Google
MXCT Stock Analysis — MAXCYTE INC (Healthcare >> Medical Devices)
MXCT FAQ
What is MXCT's ROE?
MAXCYTE INC reports a Return on Equity (ROE) of -23.30%.
What is MXCT's dividend yield?
MAXCYTE INC offers a dividend yield of 0.00%.
What is MXCT's Quality Score?
Our AI rates MXCT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MXCT?
Our AI Timing Score for MXCT is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MXCT belong to?
MAXCYTE INC is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange
MXCT AI Analysis Summary
Our AI summary for MXCT: MAXCYTE INC (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 0.00, ROE of -23.30%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.05
Price
0.00
(0.00%)
Day Change
|
|
|---|
MXCT, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.05 |
| PBV / Sector |
0.67 / -101.57
GREAT
|
| Earning Per Share | -0.37 |
| PE / Sector |
N/A / 31.23
|
| PEG or PE/Growth / Sector |
N/A / 0.40
|
| Average 1M Daily Value |
1.24 M
GREAT
|
| Average 1W Daily Value |
0.93 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:12 |
| Symbol | MXCT |
| Name | MAXCYTE INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 107.12 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 112.48 / 20,104.97 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9713 Key West Avenue, Rockville, MD, United States, 20850
Phone: 301 944 1700
Website: https://www.maxcyte.com
Employees: 91
Sector: Healthcare >> Medical Devices
Description: MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
